Form 4: Veracyte Officer Sells Shares Under 10b5-1 Plan

Veracyte's VP, Chief Accounting Officer, Jonathan Wygant, reported the sale of 10,920 shares of common stock in two transactions under a pre-arranged 10b5-1 trading plan.

Summary

• Jonathan Wygant, VP, Chief Accounting Officer of Veracyte, Inc. (VCYT), reported sales of common stock.
• On November 7, 2025, Wygant sold 5,818 shares at a weighted average price of $40.2078 per share, with individual sale prices ranging from $40.06 to $40.958.
• On November 10, 2025, Wygant sold an additional 5,102 shares at a weighted average price of $42.3321 per share, with individual sale prices ranging from $42.2866 to $42.4436.
• These transactions were conducted under a Rule 10b5-1(c) pre-arranged trading plan.
• Following these sales, Wygant beneficially owns 38,745 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider sales under a 10b5-1 plan, which is a neutral event. While it reduces insider ownership, the pre-scheduled nature mitigates concerns about opportunistic selling based on negative news.

Positives

• The sales were conducted under a Rule 10b5-1 plan, indicating a pre-scheduled transaction rather than an opportunistic sale based on new, non-public information, which generally mitigates concerns about insider selling.

Negatives

• Officer sales, even under a 10b5-1 plan, reduce insider ownership, which some investors may view as a slight negative signal regarding future prospects or management's conviction, although this is often part of routine financial planning.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider sales, particularly those executed under a 10b5-1 plan, are common in the biotechnology and diagnostics industry as executives diversify their holdings or manage liquidity. These transactions typically do not reflect a change in the company's operational performance or strategic direction, but rather personal financial planning.

Comparison to Industry Standards

• Not applicable. This filing reports an individual insider transaction, which is not typically compared to industry-wide operational or financial benchmarks.

Stakeholder Impact

• Shareholders: A slight reduction in insider ownership, though mitigated by the 10b5-1 plan, might be noted by some investors. The sales occurred at prices between $40.06 and $42.4436, providing a reference point for recent insider activity.

Next Steps

• This filing does not mention any specific future actions, events, or milestones for the company.

Key Dates

Recommendation

The filing details routine insider sales executed under a pre-arranged 10b5-1 plan. Such transactions are generally considered neutral events as they reflect personal financial planning rather than a change in the company's fundamental outlook or performance. Therefore, this specific filing alone does not warrant a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

Veracyte, VCYT, Insider Trading, Form 4, Stock Sale, Jonathan Wygant, 10b5-1 Plan, Officer Transaction, Biotech, Diagnostics